Zhang 2025 synthesized vaccine-related priorities from the 2024 update of the WHO Public Health Research Agenda for Influenza, integrating evidence from systematic literature reviews, consultations, and analysis of lessons learned from recent health emergencies, to outline a research and policy roadmap for zoonotic and pandemic influenza vaccine preparedness.
Krammer 2023 reviewed COVID-19 vaccine development during the pandemic and highlighted scientific, technological, and policy issues that need to be addressed for pandemic preparedness, including the need to provide sufficient R&D funding and to counteract vaccine hesitancy, misinformation, and anti-vax conspiracy movements.
Palache 2023 (IFPMA) summarized lessons learned for vaccine manufacturing during a pandemic (e.g., regarding pathogen surveillance and data sharing, equitable distribution, and pharmaceutical partnerships to accelerate R&D and manufacturing).
Arinaminpathy 2022 summarized lessons learned for influenza vaccine R&D from the COVID-19 pandemic in the topic areas of epidemiological implications, economic implications, global production capacity, and roles for donors and policy-makers.
Ballou 2022, NASEM 2022: the National Academy of Medicine (collaborator: US CDC/PIVI) convened a workshop focused on lessons learned from COVID-19 to inform and advance pandemic and seasonal influenza vaccine preparedness efforts and subsequent response.
See discussion paper
See workshop proceedings
Johnson 2022 (BARDA) summarized lessons learned from the development of COVID-19 vaccines, including gaps and challenges that must be addressed to prepare for future outbreaks caused by pandemic viruses.